SINTX Technologies Publishes Landmark Study Demonstrating Broad-Spectrum Antiviral Activity of Silicon Nitride
SINTX Technologies (NASDAQ: SINT) has published groundbreaking research demonstrating its silicon nitride (Si鈧僋鈧�) material's powerful antiviral properties against multiple virus strains, including SARS-CoV-2 and MERS-CoV. The study showed up to 99.97% reduction in SARS-CoV-2 within 10 minutes of contact.
As the only FDA-cleared and ISO-certified silicon nitride manufacturer in the U.S., SINTX is targeting the infection-prevention market, estimated to reach $230 billion by 2032. The company aims to commercialize applications in wound care, surgical equipment, PPE, and medical textiles. Silicon nitride offers advantages over traditional antimicrobials, being non-toxic to mammalian cells while effectively neutralizing pathogens.
SINTX Technologies (NASDAQ: SINT) ha pubblicato ricerche rivoluzionarie che dimostrano le potenti propriet脿 antivirali del suo materiale in nitruro di silicio (Si鈧僋鈧�) contro pi霉 ceppi virali, inclusi SARS-CoV-2 e MERS-CoV. Lo studio ha rilevato una riduzione fino al 99,97% di SARS-CoV-2 entro 10 minuti di contatto.
Unica negli Stati Uniti come produttrice di nitruro di silicio approvata dalla FDA e certificata ISO, SINTX si rivolge al mercato della prevenzione delle infezioni, stimato raggiungere 230 miliardi di dollari entro il 2032. L'azienda punta a commercializzare applicazioni in cura delle ferite, strumenti chirurgici, DPI e tessuti medici. Il nitruro di silicio presenta vantaggi rispetto agli antimicrobici tradizionali: 猫 non tossico per le cellule dei mammiferi ma efficace nel neutralizzare i patogeni.
SINTX Technologies (NASDAQ: SINT) ha publicado una investigaci贸n pionera que demuestra las potentes propiedades antivirales de su material de nitruro de silicio (Si鈧僋鈧�) frente a m煤ltiples cepas virales, incluyendo SARS-CoV-2 y MERS-CoV. El estudio mostr贸 hasta un 99,97% de reducci贸n de SARS-CoV-2 en 10 minutos de contacto.
Como la 煤nica fabricante estadounidense de nitruro de silicio autorizada por la FDA y certificada por ISO, SINTX se orienta al mercado de prevenci贸n de infecciones, estimado en 230 000 millones de d贸lares para 2032. La compa帽铆a pretende comercializar aplicaciones en cuidado de heridas, instrumental quir煤rgico, EPI y textiles m茅dicos. El nitruro de silicio ofrece ventajas frente a los antimicrobianos tradicionales: no es t贸xico para las c茅lulas de mam铆feros y neutraliza eficazmente a los pat贸genos.
SINTX Technologies (NASDAQ: SINT)電� 歆堩檾攴滌唽(Si鈧僋鈧�) 靻岇灛臧� SARS-CoV-2鞕� MERS-CoV毳� 韽暔頃� 鞐煬 氚旍澊霟姢 攴犾＜鞐� 雽�頃� 臧曤牓頃� 頃皵鞚措煬鞀� 韸轨劚鞚� 氤挫澑雼る姅 須嶊赴鞝侅澑 鞐瓣惮 瓴瓣臣毳� 氚滍憸頄堨姷雼堧嫟. 鞐瓣惮鞐愳劀電� 鞝戩磯 10攵� 鞚措偞鞐� SARS-CoV-2毳� 斓滊寑 99.97% 臧愳唽鞁涤及鞀惦媹雼�.
氙戈淡鞐愳劀 鞙犾澕頃橁矊 FDA 鞀轨澑 氚� ISO 鞚胳鞚� 氚涭潃 歆堩檾攴滌唽 鞝滌“鞐呾泊鞚� SINTX電� 臧愳椉 鞓堧癌 鞁滌灔鞚� 氇╉憸搿� 頃橁碃 鞛堨溂氅�, 鞚� 鞁滌灔鞚� 2032雲勱箤歆� 2,300鞏� 雼煬鞐� 鞚措ゼ 瓴冹溂搿� 於旍爼霅╇媹雼�. 須岇偓電� 靸侅矘 旃橂, 靾橃垹 旮瓣惮, 臧滌澑 氤错樃 鞛ル箘(PPE) 氚� 鞚橂鞖� 靹湢 攵勳暭鞚� 靸侅毄頇旊ゼ 於旍頃橁碃 鞛堨姷雼堧嫟. 歆堩檾攴滌唽電� 韽湢毳� 靹疙彫鞐� 氍措弲靹膘澊氅挫劀霃� 氤戩洂觳措ゼ 須臣鞝侅溂搿� 氍措牓頇旐晿電� 霌� 旮办〈 頃靸濍鞝滊炒雼� 鞛レ爯鞚� 鞛堨姷雼堧嫟.
SINTX Technologies (NASDAQ: SINT) a publi茅 des recherches r茅volutionnaires d茅montrant les puissantes propri茅t茅s antivirales de son mat茅riau en nitrure de silicium (Si鈧僋鈧�) contre plusieurs souches virales, dont SARS-CoV-2 et MERS-CoV. L'茅tude a montr茅 une r茅duction allant jusqu'脿 99,97 % de SARS-CoV-2 apr猫s 10 minutes de contact.
Seule fabricante am茅ricaine de nitrure de silicium approuv茅e par la FDA et certifi茅e ISO, SINTX vise le march茅 de la pr茅vention des infections, estim茅 脿 230 milliards de dollars d'ici 2032. La soci茅t茅 pr茅voit de commercialiser des applications pour les soins des plaies, les instruments chirurgicaux, les EPI et les textiles m茅dicaux. Le nitrure de silicium pr茅sente des avantages par rapport aux antimicrobiens traditionnels : il n'est pas toxique pour les cellules des mammif猫res tout en neutralisant efficacement les agents pathog猫nes.
SINTX Technologies (NASDAQ: SINT) hat wegweisende Forschung ver枚ffentlicht, die zeigt, dass sein Siliziumnitrid-Material (Si鈧僋鈧�) starke antivirale Eigenschaften gegen眉ber mehreren Virus-St盲mmen, darunter SARS-CoV-2 und MERS-CoV, besitzt. Die Studie ergab eine Reduktion von bis zu 99,97% bei SARS-CoV-2 binnen 10 Minuten Kontaktzeit.
Als einziges in den USA FDA-zugelassener und ISO-zertifizierter Hersteller von Siliziumnitrid zielt SINTX auf den Markt zur Infektionspr盲vention, der bis 2032 auf 230 Milliarden US-Dollar gesch盲tzt wird. Das Unternehmen plant die Kommerzialisierung f眉r Wundversorgung, chirurgische Instrumente, PSA und medizinische Textilien. Siliziumnitrid bietet Vorteile gegen眉ber herk枚mmlichen antimikrobiellen Mitteln: es ist f眉r S盲ugetierzellen nicht toxisch, neutralisiert jedoch effektiv Krankheitserreger.
- Demonstrated 99.97% reduction in SARS-CoV-2 within 10 minutes of contact
- Targeting massive $230 billion infection-prevention market by 2032
- Only FDA-cleared and ISO-certified silicon nitride manufacturer in the U.S.
- Superior safety profile compared to traditional metal-based antimicrobials
- Multiple potential commercial applications in high-value medical markets
- Company transitioning from single-product focus, indicating execution risks
- Commercialization timeline and market adoption rates uncertain
- Will require partnerships and licensing deals to accelerate growth
Insights
SINTX's silicon nitride shows impressive antiviral properties, opening substantial commercial opportunities beyond orthopedics into infection control markets.
The publication of this peer-reviewed study represents a significant scientific validation for SINTX Technologies' silicon nitride (Si鈧僋鈧�) material. The data showing
What makes this particularly notable is the mechanism of action鈥攕ilicon nitride releases reactive nitrogen species that damage viral RNA and proteins without harming mammalian cells at therapeutic levels. This provides a critical advantage over metal-based antimicrobials like silver or copper, which can present toxicity concerns. The broad-spectrum activity against multiple coronavirus variants further strengthens its potential utility.
The scientific significance extends beyond the immediate findings. As the only FDA-cleared and ISO-certified silicon nitride manufacturer in the U.S., SINTX has positioned itself with significant regulatory advantages. This creates substantial barriers to entry for competitors while facilitating faster commercialization pathways for SINTX.
This research effectively transforms SINTX from a niche orthopedic implant company into a platform technology enterprise with applications spanning medical textiles, PPE, and wound care鈥攁ddressing a projected
Breakthrough findings open doors to multi-billion-dollar infection-control markets
SALT LAKE CITY, Utah, Sept. 03, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (鈥淪INTX鈥� or the 鈥淐ompany鈥�), an advanced ceramics innovator specializing in biomedical applications of silicon nitride (Si鈧僋鈧�), today announced the publication of a peer-reviewed study demonstrating that silicon nitride exhibits potent antiviral activity against multiple infectious virus strains, including SARS-CoV-2 and MERS-CoV.
The study, conducted in collaboration with Professor Kylene Kehn-Hall鈥檚 group at Virginia Polytechnic Institute and State University (Virginia Tech), further strengthens the evidence for using silicon nitride in a wide range of infection-control applications.
A Unique Infection-Control Platform
Building on its legacy as the only FDA-cleared and ISO-certified silicon nitride manufacturer, SINTX is positioning its proprietary material as a next-generation infection-prevention additive with potential applications in:
- Wound dressings that inhibit infection and accelerate healing.
- Surgical sutures with antimicrobial surfaces to reduce bacterial colonization.
- Face masks and respirators with embedded antiviral protection.
- Hospital linens and gowns offering continuous surface protection.
- HEPA filters capable of capturing and inactivating airborne pathogens.
鈥淭his study confirms that silicon nitride is much more than a high-performance implant material鈥攊t鈥檚 a safe, effective, and broad-spectrum antiviral platform,鈥� said Dr. Ryan Bock, Chief Technology Officer of SINTX Technologies and co-author of the study. 鈥淚ts ability to inactivate dangerous viruses in minutes could transform how we approach infection prevention in healthcare and beyond.鈥�
Study Findings
The study demonstrated that direct contact to alpha-phase silicon nitride (伪-Si鈧僋鈧�) reduced infectious SARS-CoV-2 titers by up to
鈥淭hese results arrive at a time when healthcare systems are actively seeking sustainable solutions to prevent future pandemics, combat antimicrobial resistance, and reduce healthcare-associated infections,鈥� said Eric Olson, Chief Executive Officer of SINTX Technologies. 鈥淎s the only U.S.-based FDA-cleared and ISO-certified silicon nitride manufacturer, we are uniquely positioned to commercialize this technology in high-value markets where safety, efficacy, and scalability matter.鈥�
Potential Market Opportunity
The global infection-prevention and control market, encompassing medical textiles, antimicrobial wound care, and PPE, is projected to exceed
Advantages Over Traditional Antimicrobials
Unlike copper, silver, or zinc additives鈥攚hich may raise toxicity or environmental concerns鈥攕ilicon nitride releases reactive nitrogen species such as ammonia and nitric oxide that are non-toxic to mammalian cells at therapeutic levels. These species damage viral RNA and proteins, rendering pathogens non-infectious without harming surrounding tissue.
Positioning for Growth
The publication marks a strategic milestone as SINTX transitions from a single-product orthopedic implant manufacturer to a platform technology company with broad applications in infection control, advanced materials, and medical devices. The company is actively pursuing partnerships and licensing opportunities to accelerate commercialization.
The full study, 鈥淎ntiviral Efficacy of Silicon Nitride Against SARS-CoV-2 and MERS-CoV: Implications for PPE Innovation鈥�, is available online through Frontiers in Microbiology
About SINTX Technologies, Inc.
Located in Salt Lake City, Utah, SINTX Technologies is an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and agribiotech applications. SINTX is a global leader in the research, development, and manufacturing of silicon nitride, and its products have been implanted in humans since 2008. Over the past several years, SINTX has utilized strategic acquisitions and alliances to enter new markets. For more information on SINTX Technologies or its materials platform, visit聽.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (鈥淧SLRA鈥�) that are subject to a number of risks and uncertainties. Forward-looking statements include statements regarding SINTX Technologies鈥� expectations, beliefs, plans, strategies, potential applications, commercialization efforts, future market opportunities, and positioning for growth. These forward-looking statements include statements regarding: the potential for silicon nitride to serve as a next-generation infection-prevention additive; anticipated applications in wound dressings, surgical sutures, face masks, respirators, hospital linens, gowns, and HEPA filters; the Company鈥檚 belief that its technology can transform infection prevention; its plans to commercialize silicon nitride-based products and capture market share; the Company鈥檚 transition to a platform technology company; and its pursuit of partnerships and licensing opportunities to accelerate commercialization. Forward-looking statements are based on management鈥檚 current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks and uncertainties include, but are not limited to, the Company鈥檚 ability to successfully develop, manufacture, and commercialize new products; regulatory approvals; competition; market acceptance; intellectual property protection; and other factors described in the Company鈥檚 Risk Factors disclosure in its Annual Report on Form 10-K, filed with the SEC on March 19, 2025, and in its other filings with the Securities and Exchange Commission. SINTX undertakes no obligation to update or revise any forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law.
Business and Media Inquiries for SINTX:
Elliot Sloane
ThroughCo Communications
917-291-0833
Katie Russo
ThroughCo Communications
501-282-5069
SINTX Technologies, Inc.
801.839.3502
FAQ
What were the key findings of SINTX Technologies' antiviral study for silicon nitride?
What is the market potential for SINTX Technologies' silicon nitride technology?
How does SINTX's silicon nitride compare to traditional antimicrobial materials?
What are the potential commercial applications for SINTX Technologies' silicon nitride?
What is SINTX Technologies' current market position in silicon nitride manufacturing?
